

# Arvind Dasari

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/130138/publications.pdf>

Version: 2024-02-01

76  
papers

5,641  
citations

236833

25  
h-index

82499

72  
g-index

76  
all docs

76  
docs citations

76  
times ranked

7096  
citing authors

#	ARTICLE	IF	CITATIONS
1	Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. <i>JAMA Oncology</i> , 2017, 3, 1335.	3.4	2,289
2	Phase II Pilot Study of Vemurafenib in Patients With Metastatic <i>BRAF</i> -Mutated Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 4032-4038.	0.8	583
3	Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018. <i>JAMA Oncology</i> , 2019, 5, e191870.	3.4	348
4	Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. <i>Lancet Oncology</i> , The, 2017, 18, 525-534.	5.1	271
5	Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes. <i>Clinical Cancer Research</i> , 2018, 24, 1062-1072.	3.2	225
6	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal Anal Task Forces whitepaper. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 757-770.	12.5	218
7	Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases. <i>Cancer</i> , 2018, 124, 807-815.	2.0	169
8	Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences?. <i>Current Oncology Reports</i> , 2021, 23, 43.	1.8	131
9	Progression-Free Survival Remains Poor Over Sequential Lines of Systemic Therapy in Patients With <i>BRAF</i> -Mutated Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2014, 13, 164-171.	1.0	108
10	Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials. <i>British Journal of Cancer</i> , 2020, 122, 1309-1314.	2.9	77
11	Who Should Get Lateral Pelvic Lymph Node Dissection After Neoadjuvant Chemoradiation?. <i>Diseases of the Colon and Rectum</i> , 2019, 62, 1158-1166.	0.7	74
12	<i>FBXW7</i> missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 39268-39279.	0.8	69
13	Association of <i>SMAD4</i> mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. <i>PLoS ONE</i> , 2017, 12, e0173345.	1.1	65
14	Prognostic Value of Lymph Node Status and Extent of Lymphadenectomy in Pancreatic Neuroendocrine Tumors Confined To and Extending Beyond the Pancreas. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 1966-1974.	0.9	60
15	Representativeness of Black Patients in Cancer Clinical Trials Sponsored by the National Cancer Institute Compared With Pharmaceutical Companies. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa034.	1.4	59
16	Carcinoid heart disease. <i>Heart</i> , 2017, 103, 1488-1495.	1.2	56
17	Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4146-4154.	3.2	50
18	Circulating Tumor DNA Defined Minimal Residual Disease in Solid Tumors: Opportunities to Accelerate the Development of Adjuvant Therapies. <i>Journal of Clinical Oncology</i> , 2018, 36, 3437-3440.	0.8	47

#	ARTICLE	IF	CITATIONS
19	A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer. <i>Investigational New Drugs</i> , 2013, 31, 115-125.	1.2	46
20	High-Grade Neuroendocrine Colorectal Carcinomas: A Retrospective Study of 100 Patients. <i>Clinical Colorectal Cancer</i> , 2016, 15, e1-e7.	1.0	41
21	Regional lymph node involvement and outcomes in appendiceal neuroendocrine tumors: a SEER database analysis. <i>Oncotarget</i> , 2017, 8, 99541-99551.	0.8	41
22	The Treatment of Colorectal Cancer During Pregnancy: Cytotoxic Chemotherapy and Targeted Therapy Challenges. <i>Oncologist</i> , 2016, 21, 563-570.	1.9	40
23	Role of Fluorouracil, Doxorubicin, and Streptozocin Therapy in the Preoperative Treatment of Localized Pancreatic Neuroendocrine Tumors. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 155-163.	0.9	34
24	Incidence and Survival Outcomes in Patients with Lung Neuroendocrine Neoplasms in the United States. <i>Cancers</i> , 2021, 13, 1753.	1.7	33
25	Preoperative Fluorouracil, Doxorubicin, and Streptozocin for the Treatment of Pancreatic Neuroendocrine Liver Metastases. <i>Annals of Surgical Oncology</i> , 2018, 25, 1709-1715.	0.7	32
26	Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma. <i>British Journal of Cancer</i> , 2019, 121, 505-510.	2.9	32
27	Comprehensive Clinical and Molecular Characterization of KRAS <sup>G12C</sup> -Mutant Colorectal Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 613-621.	1.5	31
28	Tumor Sidedness, Recurrence, and Survival After Curative Resection of Localized Colon Cancer. <i>Clinical Colorectal Cancer</i> , 2021, 20, e53-e60.	1.0	24
29	Geographic and demographic features of neuroendocrine tumors in the United States of America: A population-based study. <i>Cancer</i> , 2020, 126, 792-799.	2.0	22
30	Novel therapeutics for patients with well-differentiated gastroenteropancreatic neuroendocrine tumors. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110180.	1.4	21
31	Carcinoid Syndrome and Costs of Care During the First Year After Diagnosis of Neuroendocrine Tumors Among Elderly Patients. <i>Oncologist</i> , 2017, 22, 1451-1462.	1.9	20
32	National Cancer Institute (NCI) state of the science: Targeted radiosensitizers in colorectal cancer. <i>Cancer</i> , 2019, 125, 2732-2746.	2.0	19
33	Epidemiology and Molecular-Pathologic Characteristics of CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2021, 20, 137-147.e1.	1.0	17
34	Alteration of FBXW7 is Associated with Worse Survival in Patients Undergoing Resection of Colorectal Liver Metastases. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 186-194.	0.9	17
35	Octreotide LAR Dosage and Survival Among Elderly Patients With Distant-Stage Neuroendocrine Tumors. <i>Oncologist</i> , 2016, 21, 308-313.	1.9	16
36	Racial Differences in the Incidence and Survival of Patients With Neuroendocrine Tumors. <i>Pancreas</i> , 2019, 48, 1373-1379.	0.5	15

#	ARTICLE	IF	CITATIONS
37	Efficacy and safety of surufatinib in United States (US) patients (pts) with neuroendocrine tumors (NETs).. Journal of Clinical Oncology, 2020, 38, 4610-4610.	0.8	15
38	FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer. Future Oncology, 2021, 17, 3151-3162.	1.1	14
39	Survival According to Primary Tumor Location, Stage, and Treatment Patterns in Locoregional Gastroenteropancreatic High-grade Neuroendocrine Carcinomas. Oncologist, 2022, 27, 299-306.	1.9	14
40	Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors. JAMA Oncology, 2022, 8, 904.	3.4	13
41	Costs of Cancer Care for Elderly Patients with Neuroendocrine Tumors. Pharmacoeconomics, 2018, 36, 1005-1013.	1.7	11
42	Loss of DPC4/SMAD4 expression in primary gastrointestinal neuroendocrine tumors is associated with cancer-related death after resection. Surgery, 2017, 161, 753-759.	1.0	10
43	Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study. Oncologist, 2019, 24, 1066-1075.	1.9	10
44	The Provocative Roles of Platelets in Liver Disease and Cancer. Frontiers in Oncology, 2021, 11, 643815.	1.3	10
45	The Future of ctDNA-Defined Minimal Residual Disease: Personalizing Adjuvant Therapy in Colorectal Cancer. Clinical Colorectal Cancer, 2022, 21, 89-95.	1.0	10
46	Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016. JAMA Network Open, 2022, 5, e2213588.	2.8	10
47	Atypical Metastatic Presentations in Colorectal Cancer: A Case Series. Clinical Colorectal Cancer, 2014, 13, e1-e4.	1.0	9
48	Loss of Menin Expression by Immunohistochemistry in Pancreatic Neuroendocrine Tumors. Pancreas, 2019, 48, 510-513.	0.5	9
49	Fluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors. Neuroendocrinology, 2022, 112, 34-42.	1.2	9
50	Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review Study. Oncologist, 2019, 24, 1056-1065.	1.9	8
51	Surgical resection and survival outcomes in metastatic young adult colorectal cancer patients. Cancer Medicine, 2021, 10, 4269-4281.	1.3	8
52	Moving Beyond the Momentum: Innovative Approaches to Clinical Trial Implementation. JCO Oncology Practice, 2021, 17, 607-614.	1.4	7
53	Impacts of pembrolizumab therapy on immune phenotype in patients with high-grade neuroendocrine neoplasms. Cancer Immunology, Immunotherapy, 2021, 70, 1893-1906.	2.0	7
54	Direct costs of carcinoid syndrome diarrhea among adults in the United States. World Journal of Gastroenterology, 2019, 25, 6857-6865.	1.4	7

#	ARTICLE	IF	CITATIONS
55	Prognosis for Poorly Differentiated, High-Grade Rectal Neuroendocrine Carcinomas. <i>Annals of Surgical Oncology</i> , 2022, 29, 2539-2548.	0.7	6
56	The Role of the Microbiome in Gastroentero-Pancreatic Neuroendocrine Neoplasms (GEP-NENs). <i>Current Issues in Molecular Biology</i> , 2022, 44, 2015-2028.	1.0	5
57	Update on management of midgut neuroendocrine tumors. <i>International Journal of Endocrine Oncology</i> , 2016, 3, 175-189.	0.4	4
58	The 1, 2, 3, 4 of carcinoid heart disease: Comprehensive cardiovascular imaging is the mainstay of complex surgical treatment (Review). <i>Oncology Letters</i> , 2019, 17, 4126-4132.	0.8	4
59	Work productivity burden and indirect costs associated with carcinoid syndrome diarrhea. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2020, 20, 507-511.	0.7	4
60	It's not a mystery, it's in the history: Multidisciplinary management of multiple endocrine neoplasia type 1. <i>Ca-A Cancer Journal for Clinicians</i> , 2021, 71, 369-380.	157.7	4
61	Colorectal cancer during pregnancy or postpartum: Case series and literature review. <i>Obstetric Medicine</i> , 0, , 1753495X2110412.	0.5	4
62	Comparison of Design, Eligibility, and Outcomes of Neuroendocrine Neoplasm Trials Initiated From 2000 to 2009 vs 2010 to 2020. <i>JAMA Network Open</i> , 2021, 4, e2131744.	2.8	4
63	[177Lu-DOTA0,Tyr3]-octreotate in the treatment of midgut neuroendocrine tumors. <i>Future Oncology</i> , 2016, 12, 313-321.	1.1	3
64	FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival. <i>Clinical Colorectal Cancer</i> , 2020, 19, 248-255.e6.	1.0	3
65	Underreporting of race/ethnicity in COVID-19 research. <i>International Journal of Infectious Diseases</i> , 2021, 108, 419-421.	1.5	3
66	Incidence of Lymph Node Metastases and Impact of Radical Surgery for Duodenal Neuroendocrine Tumors. <i>Journal of Surgical Research</i> , 2021, 268, 419-431.	0.8	3
67	Patient-reported Symptom Outcomes and Microsatellite Instability in Patients With Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2020, 19, 48-56.e2.	1.0	2
68	Targeted Therapies in the Management of Well-Differentiated Digestive and Lung Neuroendocrine Neoplasms. <i>Current Treatment Options in Oncology</i> , 2020, 21, 96.	1.3	2
69	The immune impact of PI3K-AKT pathway inhibition in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 154-154.	0.8	2
70	Predictors and Outcomes of Minimally Invasive Surgery for Small Bowel Neuroendocrine Tumors. <i>Journal of Gastrointestinal Surgery</i> , 2022, 26, 1252-1265.	0.9	2
71	Clinical and pathologic features correlated with rare favorable survival in patients with BRAFV600E mutated colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 647-656.	0.6	2
72	Abdominal Manifestations of Neuroendocrine Tumors. <i>Digestive Disease Interventions</i> , 2019, 03, 014-029.	0.3	1

#	ARTICLE	IF	CITATIONS
73	Pharmacotherapy for unresectable metastatic colorectal cancer. Expert Opinion on Pharmacotherapy, 2021, , 1-10.	0.9	1
74	Initial treatment of well-differentiated neuroendocrine tumors. Oncology, 2014, 28, 945-7.	0.4	1
75	Benchmarking Outcomes for Definitive Treatment of Young-Onset, Locally Advanced Rectal Cancer. Clinical Colorectal Cancer, 2021, , .	1.0	0
76	Report from American Society of Clinical Oncology Symposium 2020 and ASCO Gastrointestinal Cancer Symposium 2021. Diseases of the Colon and Rectum, 2021, Publish Ahead of Print, 8-10.	0.7	0